FDA Authorises Lallemand Vitamin D2 Yeast for US Food Fortification, Expands Vegan Options
The US FDA has authorised Lallemand's Lalmin Vita D2 inactive baker's yeast, broadening vitamin D fortification opportunities for American food and supplement manufacturers, particularly within plant-based categories. This regulatory update offers a naturally-derived, stable vitamin D source that aligns with growing consumer demand for clean-label, vegan ingredients.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
London, United Kingdom — 09 October 2026
The US Food and Drug Administration (FDA) has granted authorisation for Lallemand's Lalmin Vita D2 inactive baker’s yeast, enabling its use across a broader spectrum of American food and beverage applications. This approval follows the FDA's establishment of a new regulation, 21 CFR §172.383, specifically governing the ingredient. The move significantly expands options for fortification, particularly for manufacturers targeting the burgeoning plant-based sector.
Lalmin Vita D, produced by exposing Saccharomyces cerevisiae to ultraviolet light and subsequently heat-inactivating the yeast, offers a fermentation-derived, non-animal source of vitamin D2. Lallemand's Category Manager Savory Ingredients, Silvia Soragni, notes that this ingredient is particularly relevant for health-conscious consumers seeking recognisable, naturally-derived components. Commercial opportunities are strongest in plant-based dairy alternatives, protein products, beverages, meal replacements, and breakfast foods, where vitamin D sourcing can be challenging for vegan and vegetarian products, according to Soragni.
Manufacturers can expect general stability of vitamin D from Lalmin Vita D during processing, with minimal impact on taste, colour, texture, and overall product quality. This processing robustness reduces the risk of degradation during production, streamlining formulation and quality control. However, Lallemand advises manufacturers to validate the ingredient's performance within their specific formulations, processing conditions, and intended shelf life.
This US authorisation mirrors regulatory expansions seen in Europe, where UV-treated baker’s yeast was first approved as a novel food in 2014. The European Commission broadened its approved uses in 2022 to include categories such as protein products, dairy and meat alternatives, and meal replacements, providing Lallemand with established experience in diverse food matrices.
What this means for United States
US supplement manufacturers and brand owners gain a new, compliant route for vitamin D fortification, especially critical for plant-based and 'clean-label' product lines. Procurement teams should evaluate Lalmin Vita D for its competitive pricing and supply chain stability compared to other vitamin D sources. Reformulation windows now exist for brands to upgrade existing products or launch new ones meeting the escalating demand for naturally-derived and vegan-friendly ingredients. Brands can leverage the ingredient's fermented yeast origin in their marketing, differentiating offerings in a crowded market and potentially boosting consumer acceptance and market share within the £6.4 billion US plant-based sector.
This approval opens avenues for product innovation that directly respond to consumer preferences for transparency and sustainable ingredient sourcing, providing a commercial advantage for early adopters.
Many leading brands in this category are manufactured in partnership with Supplement Factory.